About Soligenix
Soligenix is a publicly listed company based in Princeton (United States) founded in 1987. Small molecule therapeutics for rare diseases are developed. The company has 16 employees. Its chief executive, as recorded, is Christopher Schaber. Its website soligenix.com draws about 12 thousand monthly visits. Soligenix offers products and services including HyBryte, SGX302, SGX942, SGX945, and SGX203. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is Soligenix, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Soligenix (formerly DOR BioPharma) develops small molecule therapeutics for rare diseases. Its most advanced candidate is in phase III trials for cutaneous T-cell lymphoma and has received both orphan designation and fast track status for the same. In addition, the company has two candidates in phase II trials for Crohns disease and oral mucositis in head and neck cancer, and a candidate for radiation enteritis in phase I trials. Soligenix also has a pipeline of vaccines for Ricin toxicity, GI acute radiation syndrome, and melioidosis.
- Net Profit-$11.08 M (USD)-34.04as on Dec 31, 2025
- EBITDA-$11.84 M (USD)-23.96as on Dec 31, 2025
- Latest Funding Round$2.6M (USD), Grant
Sep 2022
- InvestorsNIH
& 13 more
- Employee Count16
Products & Services of Soligenix
Soligenix offers a comprehensive portfolio of products and services, including HyBryte, SGX302, SGX942, SGX945, and SGX203.
Treatment for cutaneous T-cell lymphoma in rare disease applications
Treatment for mild to moderate plaque psoriasis
Therapy for oral mucositis in medical conditions
Treatment for aphthous ulcers associated with Behçet’s disease
Therapy for pediatric Crohn’s disease
Vaccine to prevent ricin poisoning in biodefense
Apps and channels of Soligenix
its YouTube channel Soligenix, Inc. has 816 subscribers and 30 videos.
Videos from Soligenix
The most watched videos on Soligenix's YouTube channel, Soligenix, Inc. (816 subscribers). Click a video to play it here.
More on Soligenix, Inc..
Funding Insights of Soligenix
- Total Rounds 24
- Last Round Grant — $2.6M
- First Round $2.38M
(Jan 2009)
- Investors Count 14
Latest 10 of 24 funding rounds of Soligenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $2.6M | Grant | – | – | |
| Jun 2021 | $865,000 | Grant | – | – | |
| Dec 2020 | $1.5M | Grant | – | – | |
| Dec 2020 | $2.1M | Grant | – | – | |
| Dec 2020 | $20M | Post-IPO | – | – | |
| Aug 2019 | $150,000 | Grant | – | – | |
| Nov 2017 | $5.12M | Post-IPO | – | – | – |
| Aug 2015 | $10M | Post-IPO | – | – | – |
| Apr 2014 | $225,000 | Grant | – | – | |
| Mar 2014 | $298,530 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Soligenix
Soligenix has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and U.S. Food and Drug Administration.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Late-stage venture capital is provided to US life sciences companies. | thirdsecurity.com | Radford, United States | ||
Investments are focused on life science and healthcare innovations. | opuspointpartners.com | |||
Investment services are offered by Iroquois Capital Group. | iroquoiscg.com | Nashville, United States | ||
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products. | fda.gov | United States | ||
Economic development services are provided by NJEDA in New Jersey. | njeda.com | Trenton, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Research on dental and craniofacial health is conducted. | nidcr.nih.gov | Bethesda, United States | ||
| sigmatau.com |
Investor details for Soligenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Soligenix
13 people are tracked at Soligenix (6 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Christopher Schaber | CEO | Leadership |
Christopher J. Schaber | President & CEO | Leadership |
Jonathan Guarino | Senior Vice President and Chief Financial Officer | Leadership |
Richard C. Straube | Senior Vice President and Chief Medical Officer | Leadership |
Oreola Donini | Senior Vice President and Chief Scientific Officer | Leadership |
Ralph Cavalli | Vice President Biopharmaceutical Development | Leadership |
Timothy R. Coté | Director | Board & advisors |
Diane L. Parks | Board Of Directors | Board & advisors |
Gregg A. Lapointe | Director | Board & advisors |
Robert J. Rubin | Director | Board & advisors |
Jerome Zeldis | Director | Board & advisors |
Roxanne Weisbrot | Corporate Controller | Team |
Sarah Millen | Finance Manager | Team |
Complete people profiles for Soligenix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Soligenix
Soligenix is a publicly listed company on the NASDAQ with ticker symbol SNGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Mar 2021
- Listed onLSE: 0A6I
- Listed entitySoligenix, Inc.
- Exchange sectorHealth technology
- ISINUS8342236044
- Share price$0.33 (-4.81% on the day) · 2026-10-13
- Market capitalisation$7.3M
- EPS (diluted, trailing year)$-1.27
- Volume (last session)267,424
Financials of Soligenix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$11.1M | -$11.8M | |
| 2024 | -$8.3M | -$9.6M | |
| 2023 | -$6.1M | -$8.4M | |
| 2022 | $250,000 | -$13.8M | -$14.5M |
| 2021 | $33,350 | -$12.6M | -$13.4M |
Detailed financial statements for Soligenix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Soligenix
4 dated milestones of Soligenix across 35 years, from founding to its latest funding, stage changes and deals.
- Founded Soligenix is founded.
- Funding First funding round of $2.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $2.6M.
Competitors of Soligenix
Soligenix has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Soligenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Soligenix
The website of Soligenix (soligenix.com) receives about 12K visits a month and ranks #2,294,239 among all websites worldwide, #3,145 in Biotechnology and Pharmaceuticals.
- Monthly visits12K
▲ 22.3% vs previous month
- Unique visitors4K
per month
- Global rank#2,294,239
among all websites
- Category rank#3,145
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit28 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Soligenix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sorrentotherapeutics.com | 100% | 1.4K | #12,489,091 | View details | |
| revance.com | 94% | 17.8K | #1,318,141 | View details | |
osmotica.com | osmotica.com | 93% | – | ||
novartis.net | novartis.net | 93% | – | ||
towradgibeachhotel.com.au | towradgibeachhotel.com.au | 65% | #2,197,781 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Soligenix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Soligenix (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Soligenix
Complete news archive for Soligenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Soligenix
Soligenix was founded in 1987 and raised its 1st funding round 22 years after it was founded.
Soligenix is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Christopher Schaber is the CEO of Soligenix, as recorded in our data.
Soligenix has 16 employees.
Soligenix (formerly DOR BioPharma) develops small molecule therapeutics for rare diseases. Its most advanced candidate is in phase III trials for cutaneous T-cell lymphoma and has received both orphan designation and fast track status for the same. In addition, the company has two candidates in phase II trials for Crohns disease and oral mucositis in head and neck cancer, and a candidate for radiation enteritis in phase I trials. Soligenix also has a pipeline of vaccines for Ricin toxicity, GI acute radiation syndrome, and melioidosis.
Soligenix's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Soligenix offers HyBryte, SGX302, SGX942, SGX945, and 2 more products and services.
Yes, Soligenix is publicly traded on NASDAQ under the ticker symbol SNGX.
Soligenix has 14 investors. Key investors include NIH, HHS, U.S. Food and Drug Administration, NJEDA, and Pontifax Venture Capital.
Soligenix operates through Soligenix, Inc..